Introduction
Blood clot dissolution in occluded vessels by systemic thrombolysis or endovascular procedures is an effective therapy for stroke patients. Although recently extended, the time window for such procedures is short (Powers et al., 2018) . For this reason, intensive research efforts have been undertaken during the last decades to develop neuroprotective treatments to minimize damage to the central nervous system (CNS) and neuroinflammation has been regarded as a particularly interesting target for therapy. Immune cell infiltration and microglia activation are regularly present in stroke, not only in the initial stages of lesion formation, but even several days after the inciting event (Jin et al., 2010) . It can be successfully targeted in experimental models by interfering with components of both the adaptive and innate immune system. However, while experimentally induced stroke could be ameliorated by targeting e.g. microglia activation via minocycline (Xu et al., 2004) or integrin-mediated recruitment of neutrophils (Jiang et al., 1998) and leukocytes (Liesz et al., 2011b) , none of these treatments have so far made it into clinical practice. In the "Neuroprotection With Minocycline Therapy for Acute Stroke Recovery Trial" (NeuMAST), the minocycline group failed to show superior long-term recovery in comparison to placebo and also the "Acute Stroke Therapy by Inhibition of Neutrophils" (ASTIN) trial using a recombinant neutrophil inhibitory factor (UK-279, 276) did not improve recovery of stroke patients (Krams et al., 2003) . Blockade of leukocyte entry via natalizumab, as shown in the "Effect of Natalizumab on Infarct Volume in Acute Ischaemic Stroke" (ACTION) trial, failed to reduce infarct volume growth (Elkins et al., 2017) . For more detailed information on past and ongoing studies targeting the immune system in stroke, we refer to an excellent review by (Veltkamp and Gill, 2016) . The failure of beneficial effects in human trials might in part be due to the fact that in contrast to the situation in experimental rodent models, knowledge about the involvement of different immune mechanisms and their dynamic evolution in human stroke patients is limited. In this review, we shortly summarize the neuroimmunological changes in the brain of experimental stroke models and compare them to what is so far known in patients.
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Immune surveillance of the normal brain and the induction of neuroinflammation
The central nervous system is regarded as an immune privileged site, since the blood-brain barrier strictly limits the entry of leukocytes and soluble inflammatory mediators from the circulation into the brain and spinal cord (Engelhardt et al., 2017) . Thus, the presence of systemically recruited monocytes and T-cells is rare in the normal CNS parenchyma, although there appears to be a restricted influx of these cells through the choroid plexus into the cerebrospinal fluid (CSF) compartment (Ghersi-Egea et al., 2018) . T-cells, which have been activated in the periphery by recognition of their cognate antigen, can pass the normal blood-brain barrier (Ransohoff and Engelhardt, 2012) . The exact function of this limited number of brain-infiltrating leukocytes is unknown. They may just pass the tissue for immune surveillance; alternatively, they might exert neuroprotective functions (Raposo and Schwartz, 2014) . A key step for the initiation of neuroinflammation is the recognition of the specific antigen by infiltrated Tcells leading to their re-activation and local proliferation as well as to the production of pro-inflammatory cytokines (Flügel et al., 2001 ). Subsequently, the inflammatory process is propagated by a secondary recruitment of other leukocyte populations (Flügel et al., 2001; Mues et al., 2013) . The induction sequence of brain inflammation is well established for MHC class II-restricted CD4 + T-cells and may relate in a similar way to MHC class I-restricted CD8 + cells (Cabarrocas et al., 2003; Huseby et al., 2001) . B-cells are exceptionally rare in the normal CNS tissue and little is known regarding their route and mechanisms of entry in the absence of inflammation (Blauth et al., 2015) . Brain damage itself has also been associated with the influx of leukocytes from the circulation mainly driven by the production of cytokines and chemokines by activated CNS-resident cells such as neurons and glia (Llovera et al., 2017; Schilling et al., 2003) . Leukocyte infiltration can occur directly at the sites of damage, but also through the choroid plexus (Ghersi-Egea et al., 2018) and recruited and activated granulocytes and macrophages may directly augment tissue injury. Microglia and macrophages have been reported as the main source All 151; mouse: 20, 133 ) from published whole-genome microarray studies based on microdissected cortical FFPE tissue (Fischer et al., 2013; Wimmer et al., 2018) were ranked according to their expression levels and percentiles were calculated for each individual gene and dataset. Genes of interest were selected and assigned to thematic groups based on published literature (Butovsky et al., 2014; Chiu et al., 2013; David and Kroner, 2011; Gautier et al., 2012; Hametner et al., 2013; Hickman et al., 2013; Murray et al., 2014; Zhang et al., 2014) and the KEGG pathway database (http://www.genome.jp/kegg/pathway.html). Human and mouse orthologs were manually matched. For each gene of interest, the mean percentile values of human and mouse microarrays were subtracted resulting in Δpercentiles. Genes with absolute Δper-centiles of < 20 were classified as similarly abundant in human and mouse cortical tissue. Δpercentile values between −40 to −20 and 20 to 40 were rated as less and more abundant, respectively. Genes with Δpercentiles lower than −40 or higher than 40 were designated as highly differently expressed (highlighted in bold). Genes were colour-coded based on their Δpercentile values: Δpercentile < −20 = blue, Δpercentile > 20 = red. Calculations were based on published analysis strategies (Galatro et al., 2017) . Recently, transcript abundances for a selected panel of microglia core genes were compared between cortical human and mouse microglia (Galatro et al., 2017) . Percentile evaluations were conducted comparing three independent mouse studies with one human transcriptome experiment. If the presented Δpercentile values of at least one of these 3 analyses yielded the same abundance differences as seen in our comparison, the respective genes were marked by an asterisk.
of IL-1β, IL-6 and TNF-α production, which was linked to poor clinical outcome and an increased stroke volume (Lambertsen et al., 2012) . Macrophages, however, are in addition instrumental in the removal of damaged tissue (Kotter et al., 2005) as well as the production of neurotrophic and anti-inflammatory cytokines including IGF, IL-10 or TGF-β, which are important for repair process after lesion formation (Kerschensteiner et al., 2003; Lalancette-Hébert et al., 2012) .
Origin and function of microglia
The normal non-diseased CNS contains tissue-resident phagocytes comprising microglia, perivascular and meningeal macrophages as well as choroid plexus macrophages. Microglia derive from erythromyeloid progenitor cells located in the yolk sac and populate the brain during early embryonic development (Alliot et al., 1999; Ginhoux et al., 2010; Kierdorf et al., 2013) . Microglia have a profound capacity for self-renewal and in the healthy brain, they are not replaced by hematogenous monocytes. Under pathological conditions, recruited blood-derived macrophages may transform in cells phenotypically resembling microglia and perivascular/meningeal macrophages. However, when disease ceases, macrophages in the CNS parenchyma are replaced within weeks by cells from the resident microglia pool (Ajami et al., 2007; Lassmann et al., 1993) . In contrast to previous data (Hickey and Kimura, 1988) , also perivascular/meningeal macrophages originate from hematopoietic precursors during normal embryonic brain development (Goldmann et al., 2016) . However, under pathological conditions including brain irradiation used in preparation for bone marrow transplantation, they are readily replaced by bone marrow-derived myeloid cells. These monocyte-derived perivascular/meningeal macrophages may persist in the brain for longer times after the recovery from damage (Hickey and Kimura, 1988; Unger et al., 1993) .
Microglia in the normal brain show a ramified "resting" morphological phenotype and express a cell type-specific set of homeostatic markers such as FCRLS or P2RY12 (see Table 1 for an extended gene list) (Butovsky et al., 2014) , of which P2RY12 is currently the most established marker for immunohistochemical labelling of homeostatic microglia (Mildner et al., 2017) . As shown in experimental models, pathological changes within the CNS lead to a downregulation of the homeostatic gene signature (Keren-Shaul et al., 2017; Krasemann et al., 2017; Verheijden et al., 2015) . Furthermore, transcriptome studies have revealed microglia-specific expression profiles (Butovsky et al., 2014; Chiu et al., 2013; Gautier et al., 2012; Hickman et al., 2013; Zhang et al., 2014) . Of these, TMEM119 has emerged as valuable immunohistochemical marker for the differentiation between CNS-resident microglia (TMEM119 positive) and blood-derived macrophages (TMEM119 negative) (Bennett et al., 2016; Satoh et al., 2016) . Recently, the TREM2 pathway and APOE-dependent mechanisms have been described as regulators for microglia switching to a neurodegenerative phenotype (Keren-Shaul et al., 2017; Krasemann et al., 2017; Lee et al., 2018) . Moreover, it was determined that the recognition of apoptosis-related surface antigens present on damaged cells induces the transition from homeostatic non-phagocytic to amoeboid-phagocytic microglia (Krasemann et al., 2017) . It has been suggested that this first microglia activation step induces "alerted" microglia, which mainly have neuroprotective functions. Depending on addition local cues, such as inflammatory cytokines or various exogenous or endogenous Tolllike receptor ligands, microglia can further transform into a variety of different phenotypes promoting inflammation or neurodegeneration (Krasemann et al., 2017; Perry et al., 2010) . For these reasons, it has been suggested that the preservation of a homeostatic/resting phenotype in degenerative diseases should be beneficial. However, blockade of one of the key signature molecules of homeostatic microglia, the purinergic receptor P2RY12, reduces neuronal injury in experimental stroke lesions (Webster et al., 2013) suggesting also a pathogenic role of this receptor in the propagation of tissue damage.
Neuroinflammation in experimental stroke lesions
In order to mimic the pathophysiology of human stroke, different animal models have been established. The most common techniques for disease induction include intra-arterial suture occlusion of the middle cerebral artery, craniotomy followed by electrocoagulation, photothrombosis and occlusion by a long acting vasoconstrictive peptide (endothelin-1 model) (Fluri et al., 2015; Kumar and Gupta, 2016; Yan et al., 2015) . The rather disappointing translation of experimental results into human trials led to the establishment of the Stroke Therapy Academic Industry Roundtable (STAIR), which provides recommendations for experimental studies to improve research outcomes (Fisher et al., 2009) . Since the discussion of the advantages and disadvantages between the different stroke models are beyond the scope of this review, we would like to refer for further reading to the STAIR recommendations (Fisher et al., 2009 ) as well as other reviews (Fluri et al., 2015; Kumar and Gupta, 2016) .
Experimental studies have provided ample evidence for the presence and potential pathogenic role of inflammatory cells in stroke lesions and these data have recently been summarized in a comprehensive issue in Neurotherapeutics (Becker and Buckwalter, 2016) . Thus, only the key findings will be presented here. After acute vascular occlusion, a central core of tissue necrosis forms, which is surrounded by a penumbra of variable size. While in the necrotic core of stroke lesions microglia are destroyed in parallel with neurons and glia cells, microglia located at the edge of lesions get readily activated (Zhang et al., 1997) . Using bone marrow chimeric animals that allow for the distinction between microglia-derived macrophages (GFP-negative) and peripheral monocyte-derived macrophages (GFP-positive), it was shown that within 24 h after middle cerebral artery occlusion, pronounced local proliferation and activation of resident microglia dominated within the infarct zone. Infiltration of blood-derived myeloid cells occurred later and peaked on day 7. However, at this time point, the majority of cells exhibiting macrophage morphology were GFP-negative indicating a microglial origin (Schilling et al., 2003) . The functional polarization of microglia and macrophages is currently discussed controversially. Overall, data show a dominant pro-inflammatory (M1) phenotype and these cells may be involved in the propagation of tissue injury (Xiong et al., 2016) . Depending on the experimental model, an additional expression of anti-inflammatory macrophage markers is either seen in the initial stages or at later time points of lesion formation (Hu et al., 2012; Kronenberg et al., 2018; Suenaga et al., 2015; Taylor and Sansing, 2013) . Generally, activated macrophages are instrumental for the removal of damaged tissue, which is a prerequisite for the initiation of repair processes (Kotter et al., 2005) such as remyelination and the production of neuroprotective cytokines (Neumann et al., 2009) . As described in a study analyzing a single time point (7 days after stroke), microglia and monocyte-derived macrophages differed in their gene expression profile. Microglia showed a dominant activation towards a pro-inflammatory phenotype, while recruited macrophages mainly expressed molecules associated with an anti-inflammatory function. In line with this observation, blocking the entry of recruited macrophages into the lesions exacerbated disease and infarct size (Kronenberg et al., 2018) .
The early changes of microglia activation are followed by tissue infiltration of polymorphonuclear leukocytes (neutrophils). They are already present 30 min after lesion initiation and their occurrence peaks after one to four days (Jin et al., 2010; Schilling et al., 2003) . Their recruitment appears to be driven by the release of damage-associated molecules (DAMPs) and the local expression of adhesion molecules, such as selectins and the integrin binding partners ICAM-1 and VCAM-1, and chemokines in the process of neurodegeneration induced by the production of pro-inflammatory cytokines by stressed neurons and glia (Iadecola and Anrather, 2011; Yilmaz and Granger, 2010) .
Tissue infiltration by cells of the adaptive immune system occurs at a later time point. Their presence peaks within lesions featuring the early resorption stage, when damaged tissue is already taken up by macrophages (Liesz et al., 2011b; Stevens et al., 2002) . The first wave of lymphocytes mainly includes innate γ/δ T-cells and is followed by the infiltration of classical T-and B-cells (Gelderblom et al., 2009; Shichita et al., 2009) . Within the T-cell population, MHC class II-restricted CD4 + cells dominate (Liesz et al., 2011b; Takata et al., 2012) . Whether these lymphocytes are solely bystander cells or locally recognize a brain-specific antigen is unknown (Liesz et al., 2013a) . Importantly, CD4 + T-cells may not only have pro-inflammatory functions, but counteract the inflammatory process in a lesion stage-dependent manner as regulatory T-cells (Liesz et al., 2013b) . These inflammatory processes are prominent within 1 to 7 days after lesion induction. At later stages, tissue debris-containing macrophages prevail and persist for extended periods of time. Eventually, the inflammatory responses decline and the lesions transform into scar tissue. The mere presence of different subsets of inflammatory cells in stroke lesions does not necessarily imply that they are directly causative in stroke pathogenesis. To unravel their functional roles, thus depends on experimental treatment paradigms (Anrather and Iadecola, 2016) . With respect to polymorphonuclear leukocytes, most studies indicate that blocking their migration into the lesions reduces clinical disease and lesion size (del Zoppo, 2010), although some data suggest also a protective role for one of their subsets (Cuartero et al., 2013) . Similarly, inhibiting different mechanisms of macrophage and microglia activation has shown beneficial effects in stroke models (Lampl et al., 2007; Murray et al., 2015) . However, microglia depletion in early stages may also exacerbate disease (Faustino et al., 2011; Lalancette-Hebert et al., 2007) . It is generally suggested that the blockade of pro-inflammatory differentiation of macrophages and microglia should be beneficial and anti-inflammatory M2 polarization should be promoted (Amantea et al., 2015; Kanazawa et al., 2017) . This may, however, be an oversimplification since in contrast to well-controlled cytokine-induced M1/ M2 states in in vitro experiments, macrophages and microglia activation is much more complex in in vivo pathological states and the cells present with intermediate phenotypes. As an additional caveat, in another study, neither selective or unselective macrophage depletion nor the passive transfer of M1-and M2-polarized macrophages has shown any effect in a model of transient cerebral artery occlusion (Schmidt et al., 2017) .
Beneficial effects have been seen following the depletion of γ/δ Tcells as well as classical α/β CD4 + and CD8 + T-cells (Liesz et al., 2011a; 2011b; Yilmaz et al., 2006) . Depletion of regulatory T-cells, however, led to worse outcomes (Liesz et al., 2009 ), while boosting regulatory T-and B-cell responses ameliorated disease (Bodhankar et al., 2013; Ren et al., 2011; Seifert et al., 2018) . However, boosting regulatory T-cells can also have the opposite effect in transient stroke models possibly by increasing thromboinflammation (Gauberti and Vivien, 2015) . Related to the role of T-cells in stroke lesions, it has also to be considered that the same autoreactive T-cells, which after intravenous transfer in high numbers induce autoimmune encephalitis, may mediate regulatory and neuroprotective effects, when present in smaller numbers or in a different local brain environment in neurodegenerative conditions (Schwartz and Kipnis, 2005) . Altogether, the experimental data show that inflammation in stroke lesions can have both detrimental and beneficial effects and, thus, therapeutic intervention will only be reproducibly beneficial, if it can successfully target specific mechanisms of the immune response at specific time-dependent lesion stages. Furthermore, experimental data show that the composition of inflammatory mediators in the ischemic brain also differs depending on the mode of disease induction. A comparison between permanent and transient middle cerebral artery occlusion showed an earlier recruitment of neutrophils in the transient model, while 5 days after disease induction, neutrophils were more abundant in the permanent one. Moreover, microglia activation was much more pronounced after permanent artery occlusion (Zhou et al., 2013) . Finally, the age of animals at the time of brain ischemia or hypoxia has a major effect on the outcome of the lesions. Compared to young animals, aged ones react to experimental brain ischemia with a more profound microglia activation and increased macrophage or granulocyte recruitment, which is associated with increased disease severity and brain damage (Manwani et al., 2013; Ritzel et al., 2018) .
Neuroinflammation in human stroke lesions

General patterns of inflammation
Contrary to experimental stroke models, the pathology of human stroke lesions is much more complex and a simple correlation of pathological stages with time after disease onset is not possible. Moreover, in the human situation, clear temporal and spatial separations of changes of acute neuronal injury, varying degrees of neuroinflammation as well as lesion evolution and resorption are lacking and largely overlap even within individual patients (Mena et al., 2004) . Thus, a lesion classification system has been suggested, which bases on neuropathological examination of 137 patients (Mena et al., 2004) . In this study, the authors distinguish between the stage of acute neuronal injury (disease duration: 1-2 days), the phase of organization subdivided into acute (duration: 3-37 days) and chronic inflammation (duration 10 days to 53 years) and the phase of resorption (duration of 26 days to 23 years) (Mena et al., 2004) . Time overlaps possibly occur due to heterogeneous causes of acute injury, very slow tissue reaction to acute necrosis in old patients presenting with large infarct lesions, high frequency of recurrent ischemic episodes and presence or absence of systemic co-morbidities at the time of death such as systemic inflammation or sepsis (Mena et al., 2004) . Thus, studies on inflammation in human stroke lesions are generally based on neuropathologically staged lesions and not on the time interval between disease onset and autopsy (Mena et al., 2004; Nguyen et al., 2016; Zrzavy et al., 2017b) .
The nomenclature for different lesion stages varies between studies, but can be summarized in three categories. Stage 1 is named either acute neuronal injury stage (Mena et al., 2004) , acute stroke (Nguyen et al., 2016) or initial lesion (Zrzavy et al., 2017b) . Stage 2 is termed either phase of organization (Mena et al., 2004) , liquefactive necrosis stage (Nguyen et al., 2016) or early and late resorption stage (Zrzavy et al., 2017b) . Finally, stage 3 described as resorption phase by Mena and colleagues (Mena et al., 2004) corresponds to the cystic encephalopathic stage (Nguyen et al., 2016 ) and the late cystic or scar stage (Zrzavy et al., 2017b) . Taken together, stage 1 is dominated by acute neuronal and glial injury associated with infiltration of polymorphonuclear leukocytes and an increased expression of pro-inflammatory cytokines and chemokines (Nguyen et al., 2016) . In stage 2, damaged tissue is taken up by cells with macrophage phenotype. Polymorphonuclear leukocytes may still persist in variable numbers. Finally, stage 3 is dominated by cavitation, astrocytic scaring and neovascularization (Mena et al., 2004) . While pro-inflammatory cytokines in the latter two stages have largely declined to levels seen in control brains, chemokine expression is still elevated (Nguyen et al., 2016) . Patterns of cytokine and chemokine expression are similar between human and rodent stroke lesions, when the analysis is based on comparable lesion stages (Nguyen et al., 2016) .
Microglia and macrophages in human stroke lesions
A detailed phenotypic characterization of microglia and macrophages has recently been performed using a large panel of markers to define origin and functional polarization of the cells (Zrzavy et al., 2017b) . As described before in experimental rodent models, microglia cells were nearly completely lost in the necrotic core of initial ischemic infarct lesions (stage 1) and there was profound proliferation and activation of local resident microglia in the penumbra surrounding the lesions (Fig. 1a) . At stage 2, the lesions became densely packed with macrophages containing tissue degradation products. By using a recently discovered marker (Tmem119), which allows for the distinction between cells of microglia origin and recruited blood-borne myeloid cells (Bennett et al., 2016; Butovsky et al., 2014) , it was shown that in early stage 2 lesions, most macrophages were derived from the resident microglia pool, while the contribution of recruited macrophages increased during further lesion maturation (Fig. 1b) (Zrzavy et al., 2017b) . The majority of microglia within the lesions did not express P2RY12, a purinergic receptor used as a marker for homeostatic microglia. In the early lesion stages, microglia and macrophages were functionally polarized towards a pro-inflammatory phenotype highly expressing molecules involved in antigen presentation, oxidative injury and phagocytosis. With further lesion maturation, they transformed into an intermediate phenotype co-expressing classical pro-inflammatory markers together with others typically expressed in cells in vitro polarized towards an anti-inflammatory (M2) phenotype. At the late cystic or scar stage (stage 3), macrophages disappeared but microglia re-appeared showing in part a marker profile of homeostatic cells. Overall, the phenotype of microglia and macrophages in stroke lesions was comparable to what is seen in multiple sclerosis, provided that the lesions were staged in a similar way in relation to the presence of degradation products in phagocytes. The only major difference was that microglia activation in stroke was self-limiting and resolved in chronic lesions, while it was persistent in the MS brain (Zrzavy et al., 2017a; 2017b).
Polymorphonuclear leukocytes (PMNs) in human stroke lesions
PMNs in human stroke lesions are mainly seen in lesions of stage 1 and early stage 2 (Fig. 1a) (Mena et al., 2004) . They are present in inflammatory infiltrates in the meninges and the perivascular space, however, infiltration into the lesion parenchyma is low in the majority of cases suggesting that the perivascular glia limitans is a major barrier for PMN infiltration into the damaged tissue (Enzmann et al., 2013; Perez-De-Puig et al., 2015) . Notably, a dense diffuse PMN infiltration is present in some stroke cases independent of the lesion stage (Zrzavy et al., 2017b) . The reason for these exceptions is currently not clear. It was suggested to depend on the presence of a hemorrhagic phenotype or the destructive nature of the lesion (Kalimo et al., 2013) . In addition, an age-dependent increase in granulocyte infiltration in human stroke lesions has been described (Ritzel et al., 2018) although quantitative data of this study were based on the expression of myeloperoxidase, which is not only present in granulocytes, but also in activated macrophages and microglia. A relation with age, lesions severity or a hemorrhagic component was not observed in the study by Zrzavy and colleagues (Zrzavy et al., 2017b) . Moreover, the presence or absence of PMNs in the lesions was not related to systemic inflammation or sepsis at the time of death of the patients. Fig. 1 . Inflammatory responses in ischemic stroke lesions. The general mechanisms of lesion development apply to both human and experimental stroke lesions. However, two key differences exist: First, the time course of lesion development varies between human and experimental stroke. Second, microglia in the (aged) human brain express a mixed homeostatic/pro-inflammatory marker profile, while rodent microglia show a pure homeostatic phenotype. (a) Cellular composition of stroke lesions during the initial (acute) phase, the resorption phase and within the final scar. During the initial phase, the infarct core (dark gray area) is dominated by dead cells. Sparse infiltration of the tissue by T cells and polymorphonuclear leukocytes (neutrophils) occurs. Microglia in the penumbra (medium gray area) have an activated morphology, while they keep a ramified appearance in the normal-appearing surrounding tissue (light gray area).During the resorption phase, macrophages are the prevailing cells within both core and penumbra. Some derive from microglia, while others originate from blood-derived monocytes. The final scar tissue contains both activated and ramified microglia cells. (b) Polarization patterns of microglia and macrophages during lesion evolution. Activated microglia in the penumbra of acute stroke lesions show a predominantly pro-inflammatory phenotype (red cells). Ramified microglia within the human normal-appearing tissue have a mixed homeostatic/pro-inflammatory background (blue/red cells), while in rodent models, ramified microglia have a purely homeostatic phenotype. During the resorption phase, activated microglia, microgliaderived macrophages and blood-derived macrophages within the penumbra have either a pure pro-inflammatory (red cells) or a mixed pro/anti-inflammatory (orange cells) phenotype, while pure anti-inflammatory cells (green cells) can be found within the core area. Activated and ramified microglia within the final scar tissue show a mixed homeostatic/pro-inflammatory marker profile (blue/red cells).
T-and B-cells in human stroke lesions
The overall extent of T-cell infiltration into human stroke lesions is very modest (Fig. 1a ) and about 50-to 100-times lower compared to levels seen in classical inflammatory diseases, such as encephalitides or multiple sclerosis (Machado-Santos et al., 2018) . Moreover, T-cell densities in comparatively staged human stroke lesions were substantially lower compared with levels described before in experimental rodent models (Gelderblom et al., 2009; Liesz et al., 2011b) . Despite the relatively low numbers, a significant increase became apparent in stage 2 lesions in comparison with normal human control tissue and unaffected brain tissue of stroke patients (Zrzavy et al., 2017b) . T-cell infiltrates were mainly composed of MHC class I-restricted CD8 + cells, while the contribution of CD4 + T-cells was negligible and not significantly different from controls. Local antigen-specific activation of these T-cells was unlikely, since they did not express proliferation markers (Zrzavy et al., 2017b) . In contrast to T-cells, B-cells were virtually absent during all lesion stages. Overall, the data indicate that low numbers of T-cells infiltrate human stroke lesions as a bystander consequence of tissue damage. A more detailed phenotypic and functional characterization of lymphocytes has so far not been performed in human stroke lesions, due to their very low total numbers.
Differences in microglia phenotypes in the normal non-diseased brain between humans and rodents
Although the core signature of homeostatic "resting" microglia in the normal brain is shared between humans and rodents, there are considerable species-dependent differences in gene and protein expression, which may have important implications for disease states. Furthermore, age-related changes differ fundamentally between human and mouse microglia (Galatro et al., 2017) .
Evaluating the abundance of selected gene transcripts in relation to the whole transcriptome shows that a large number of genes implicated in microglia homeostasis as well as activation is expressed to different extents between human and mouse cortex (Table 1 ). For the majority of genes of interest, transcripts were more abundant in the human tissue. The observed differences strongly suggest that in the normal human brain, microglia are in a more pre-activated/alerted state than in animals routinely used for experimental studies. This disparity is also observed on protein level as determined by immunohistochemistry (Fig. 2) . While in the normal rodent brain nearly all microglia show a homeostatic phenotype characterized by P2RY12 expression and negativity for NADPH oxidase components (e.g. p22phox) and phagocytosis-associated lysosomal markers such as Mac3 (LAMP2), the majority of microglia in the normal human brain express p22phox and CD68 (marker for phagocytic activity). Additionally, the homeostatic marker P2RY12 is only seen on a subset of cells with microglia origin. Moreover, microglia in the non-diseased human CNS can stain positive for MHC class I and class II antigens as well as co-stimulatory molecules such as CD86 (B7-2). A subset of microglia in the aging human brain reveals changes defined by the term "senescent microglia" characterized by fragmentation and loss of their cell processes and a high expression of the iron storage protein ferritin (Lopes et al., 2008; Streit et al., 2004; . The latter can be explained by age-related iron accumulation in the human brain (Hallgren and Sourander, 1958) . Immunohistochemistry for the pan-microglia/macrophage marker Iba-1, the microglia-specific markers Tmem119 and P2RY12 (Bennett et al., 2016; Butovsky et al., 2014) , p22phox as component of the oxygen radical-producing NADPH oxidase complex, the phagocytosis markers Mac3 (mouse) and CD68 (human), CD86 and HLA-DR as co-stimulatory and MHC class II-restricted antigen-presenting molecules, respectively, the iron storage molecule ferritin (staining heavy and light chain of ferritin), the haptoglobin/hemoglobin receptor CD163 and the mannose receptor CD206, one of the classical M2 markers. In the normal mouse brain, microglia express solely the homeostatic markers, while in the brain of human non-neurological controls, co-expression of a variety of additional activation markers is observed. Scale bar, 50 μm.
Microglia senescence is associated with the loss of homeostatic function or with their oxidative activation. Both of these mechanisms have been suggested to promote neurodegeneration.
Causes for the different gene transcript abundances between human and mouse cortical tissues are still enigmatic. Genuine species differences may play a role, but also systemic exposure to environmental cues such as infectious diseases, which may promote microglia activation in the absence of other pathological changes in the CNS (Shimada and Hasegawa-Ishii, 2017; Zrzavy et al., 2018) , differ between laboratory animals and humans. Finally, in contrast to experimental animals, death in humans occurs on the background of systemic comorbidities or ageand disease-related neurodegeneration, which may influence the general activation stage of microglia and affect basic studies on human microglia phenotypes. Despite the lack of knowledge on what drives microglia activation in individual patients, it should be considered that contrary to rodents, brain disease in humans generally occurs on a background of pre-activated/alerted microglia phenotypes. This may have major implications for the functional pro-inflammatory or neuroprotective state of microglia in human brain disease (Perry et al., 2010) , which may be reflected only to a limited degree in rodent models.
Conclusions
Therapeutic strategies targeting different components of the inflammatory response have shown beneficial effects in experimental models, however, their successful translation into clinics has so far failed. One likely explanation is that inflammation per se has not only detrimental but also beneficial effects. Additionally, therapeutic intervention will most probably be effective only if a specific time window during lesion evolution is targeted. This can be easily achieved in wellcontrollable experimental models, but will be very difficult in patients since the time course of lesion maturation in humans is protracted and furthermore complicated by recurrences of ischemic episodes. In addition, there are also species-dependent variations regarding the contribution of different components of the immune system to the pathogenesis of ischemic lesions. The overall involvement of cells of the adaptive immune system seems to be sparse in human lesions. Additionally, the nearly exclusive presence of MHC class I-restricted CD8 + T-cells differs from the much broader spectrum of lymphocyte populations present in rodents. Regarding microglia and macrophages, the timing and activation phenotype is similar between humans and rodents. However, human stroke lesions, which occur predominantly in aged patients, apparently arise on the background of a pre-activated phenotype of these cells, as present in the normal adult human brain. Thus, prior to the initiation of clinical trials, it should be determined via neuropathological studies whether and at what time point the respective target molecules are expressed in the human brain lesions. In addition, development of new markers for positron emission tomography should be developed to be able to define the nature and timing of the inflammatory response within the brain of stroke patients (O'Loughlin et al., 2018) . Finally, it has to be kept in mind that the knowledge about neuroinflammation in human stroke patients is still very limited. So far, it has not been systematically analyzed, to what extent the neuroinflammatory reactions differ in patients with ischemic versus hemorrhagic lesions, in patients with different stroke causes or in patients with different co-morbidities. Furthermore, systemic immune reactions may modify disease in stroke patients independent from the local action of inflammatory cells within the lesions.
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